Finerenone vs Spironolactone: The New Battle for Heart Failure Treatment
A landmark 2025 review compares old and new mineralocorticoid blockers, spotlighting finerenone's emerging edge in heart failure and kidney disease.
Summary
Steroidal mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone have long proven their worth in heart failure with reduced ejection fraction, but poor tolerability has limited their use. This 2025 review in JACC Heart Failure examines how newer nonsteroidal MRAs—particularly finerenone—and aldosterone synthase inhibitors differ structurally and mechanistically from their predecessors. Finerenone has demonstrated significant reductions in cardiovascular and renal events in type 2 diabetes with chronic kidney disease, and has also reduced cardiovascular death and heart failure hospitalizations in preserved and mildly reduced ejection fraction populations. The review highlights that head-to-head outcome trials comparing these drug classes are still lacking, and calls for continued research to clarify which patients benefit most from each approach.
Detailed Summary
Mineralocorticoid receptor antagonists (MRAs) have been a cornerstone of heart failure therapy for decades, yet their full potential remains unrealized. Drugs like spironolactone and eplerenone are effective in heart failure with reduced ejection fraction (HFrEF), but side effects—including hyperkalemia and hormonal disturbances from steroidal agents—have kept real-world prescribing rates low. Additionally, their benefit in heart failure with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) has remained uncertain.
This comprehensive 2025 review by Harrington, Vaduganathan, Solomon, and colleagues critically compares the structural, mechanistic, and clinical profiles of steroidal MRAs against a new generation of agents: nonsteroidal MRAs like finerenone, mineralocorticoid receptor modulators, and aldosterone synthase inhibitors. These newer molecules target the aldosterone-mineralocorticoid receptor axis with greater selectivity and potentially improved tolerability.
Finerenone stands out in the review for its robust clinical trial data. It has reduced cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, and has demonstrated a reduction in the composite endpoint of cardiovascular death and heart failure hospitalizations in HFmrEF and HFpEF populations—patient groups where steroidal MRAs have historically shown limited benefit.
Despite this progress, the review underscores a critical gap: no large-scale, randomized, head-to-head outcome trials yet compare steroidal versus nonsteroidal MRAs or newer aldosterone-targeting agents. Without such data, clinicians lack definitive guidance on which therapy to prioritize for which patient.
The authors call for ongoing and future research to resolve these uncertainties and better define optimal use of MRA therapy across the spectrum of heart failure, diabetes, and chronic kidney disease. For longevity-focused readers, this review highlights how precision targeting of hormonal pathways central to cardiovascular aging may yield better outcomes with fewer side effects.
Key Findings
- Finerenone reduces cardiovascular death and heart failure hospitalizations in HFmrEF and HFpEF populations.
- Steroidal MRAs (spironolactone, eplerenone) remain underused in HFrEF due to side effects and tolerability concerns.
- Nonsteroidal MRAs offer greater receptor selectivity and a potentially improved safety profile vs steroidal agents.
- Finerenone demonstrates efficacy in reducing cardiovascular and renal events in type 2 diabetes with CKD.
- No head-to-head outcome trials currently compare steroidal vs nonsteroidal MRAs or aldosterone synthase inhibitors.
Methodology
This is a narrative review published in JACC Heart Failure (2025), synthesizing evidence from randomized controlled trials, mechanistic studies, and ongoing research across heart failure, diabetes, and CKD populations. The authors compare structural and pharmacological distinctions between drug classes rather than conducting new primary research. No meta-analysis or systematic review methodology is described.
Study Limitations
The review is based only on available trial data, and the absence of direct comparative outcome studies limits conclusions about superiority between drug classes. Effectiveness in HFpEF and HFmrEF for steroidal MRAs remains uncertain, and subgroup heterogeneity across trials makes cross-study comparisons difficult. The study was authored by researchers with extensive industry ties, which may influence emphasis and framing.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.